Items where Author is "Peters, S."

Article

Lee, S. M. and Schulz, C. and Prabhash, K. and Han, B. and Szczesna, A. and Cortinovis, D. L. and Rittmeyer, A. and Vicente Baz, D. and Califano, R. and Anh, L. Tuan and Liu, G. and Cappuzzo, F. and Reyes Contreras, J. G. and Reck, M. and Hu, Y. and Morris, S. and Hoeglander, E. K. and Connors, M. and Vollan, H. K. M. and Peters, S. (2022) IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen. ANNALS OF ONCOLOGY, 33 (Suppl7). S1418-S1419. ISSN 0923-7534, 1569-8041

Conference or Workshop Item

Lee, S. M. and Han, B. and Peters, S. and Le, A. T. and Huang, D. and Wu, G. and Cao, L. and Pham, C. P. and Zhao, J. and Wang, K. and Yang, N. and Zhong, H. and Hu, Y. and Morris, S. and Lam, V. and Graupner, V. and Gitlitz, B. and Hoglander, E. and Schulz, C. (2023) Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS. In: 2023 World Conference on Lung Cancer, 09 September 2023 - 12 September 2023, Singapore.

Other

Lee, S. M. and Schulz, C. and Cardona, A. and Bartakova, P. and Peters, S. (2017) Phase III study of atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with treatment-naive advanced, recurrent or metastatic NSCLC unsuitable for platinum (plat)-based chemo. OXFORD UNIV PRESS, OXFORD.